Corporations
make a difference

Read more

Treatment

The ARSACS Foundation is now
working with pharmaceutical companies
to develop a treatment for ARSACS

Read more

Several research projects
are currently funded
by the Foundation
in Canada and abroad

Read more

The Ataxia gene can be
passed through many generations
without manifesting any symptoms

Read more

We need your support
to pursue research that heals

How can you help?

Donate
`

Latest News

July

16

2015
Dr Slaven Erceg's project in several spanish media.
Dr Slaven Erceg's research project, one of the projects funded by the Foundation for the 2015-2016 fiscal year, has received coverage in several spanish media. See Press release,Communidad,Infosalus, Valencia.

July

11

2015

$1.4M allocated to eleven ARSACS research projects for 2015-2016

The Foundation is pleased to announce that eleven research projects have been selected to share over $1.4M in research grants for its 2015-2016 research program. All applications received were evaluated by the Scientific Committee. The Foundation would like to thank all candidates who submitted a proposal.

Read More

July

07

2015

Meeting with a pharmaceutical company

On June 23, a meeting was held in Montreal between a pharmaceutical company and the ARSACS research team with respect to the outcome of the preclinical trial phase II currently underway on the ARSACS mice at the Douglas Institute. The complete results should be known in November 2015. See Summary.

June

22

2015

Opportunity to share the most recent research results

The meeting of the team of researchers “ARSACS – CIHR” held on June 3 provided an opportunity to share the most recent research results from each lab. See ARSACS meeting.

June

12

2015

Regular training has a positive impact on ARSACS patients

In February 2015,the Foundation funded a study conducted by Olivier Audet to determine the impact of a regular training program on ARSACS patients. The study shows a significant improvement for 11 of the 13 evaluations of physical fitness and the functional ability. See report(French version only) Mémoire.

June

08

2015

Preclinical therapeutic trial

The preparation required for a preclinical trial with a therapeutic molecule coming from the United States will begin soon. This test will be done on ARSACS mice in Montreal laboratories. This will be the 2nd preclinical trial funded by the Foundation. The results of the first trial are still to come.

May

24

2015

New ARSACS findings to be presented at the Neuroscience 2015 meeting

Dr. Alanna Watt, member of the ARSACS research team, will be presenting the new ARSACS findings as a poster at the Neuroscience 2015 meeting. The annual meeting of the Society of Neuroscience will be held in October 2015 in Chicago. See New findings abstract.


Who We Are


What We Do

Funding
Funding
process
Team
Research
Research
process
Discovery
Trials
Trials

The Ataxia Charlevoix-Saguenay Foundation is a charitable organisation supported entirely by private donations. Different events are organised during the year by families, friends and community groups to raise funds to support research on ARSACS.


Since its creation, the Foundation has been successful in assembling a great team at all levels of the organisation (board, advisors, researchers, contributors and partners). The researchers are well respected in their field and have an international reputation for excellence.


The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS. Several research projects on ARSACS are currently funded by the Foundation in Canada and abroad. Over 98% of the funds raised are allocated to research.


The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS.


The first therapeutic tests on transgenic ARSACS mice conducted in the Spring 2013 were very positive. For a short study, the tests demonstrated some beneficial effect on the physical performance of the mice. Discussions are underway to determine the next step.